Experience with calcipotriol as adjunctive treatment for vitiligo in patients who do not respond to PUVA alone: A preliminary study - 02/09/11
Abstract |
Background: PUVA therapy remains a primary treatment for vitiligo, despite unsatisfactory results. Because of calcipotriol's reported effects on melanocytes and on immunomodulatory and inflammatory mediators we wondered whether adding calcipotriol to PUVA would be more effective than PUVA alone in treating vitiligo. Objective: We sought to determine whether the combination of topical calcipotriol and PUVA therapy increases the responsiveness of patients with vitiligo refractory to PUVA alone. Methods: Twenty-one patients with vitiligo refractory to previous PUVA therapy were studied. Patients received 60 sessions of PUVA 3 times a week and 0.005% topical calcipotriol twice daily. Patients were monitored for repigmentation overall and on the trunk, extremities, and acral regions. Results: Starting at the median of the 17th treatment session, some degree of repigmentation was observed in 71.5% of the patients. After treatment, cosmetically acceptable overall repigmentation was observed in 29% of patients; repigmentation of lesions on the trunk, extremities, and acral region was noted in 36%, 58%, and 0% of patients, respectively. Adverse reactions were mild and tolerable. Conclusion: The combination of PUVA and calcipotriol may be effective therapy and should be further investigated for the treatment of vitiligo. (J Am Acad Dermatol 2001;44:634-7.)
Le texte complet de cet article est disponible en PDF.Plan
None of the authors had any financial relationship to any commercial association of the products used in the study that might pose a conflict of interest. The study was funded solely through Hacettepe University. |
|
J Am Acad Dermatol 2001;44:634-7 |
|
Reprint requests: Sedef Şahin, MD, Hacettepe University, Faculty of Medicine, Department of Dermatology, Sihhiye 06100 Ankara, Turkey. |
Vol 44 - N° 4
P. 634-637 - avril 2001 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?